Financial Report: Biogen Idec 4Q

Biogen Idec 4Q

4Q Revenues: $1.1 billion (+5%)

4Q Earnings: $306 million (+48%)

FY Revenues: $4.4 billion (+7%)

FY Earnings: $1.0 billion (+24%)

Comments: Tysabri revenues in the quarter increased 39% to $216 million and Avonex revenues were up 5% to $596 million. Rituxan revenues in the quarter were down 15% to $257 million. Growth for the year was driven primarily by Tysabri sales, which increased 32% to $776 million, and Avonex sales, which increased 5% to $2.3 billion. Rituxan revenues from the company’s joint business arrangement decreased 3% to $1.1 billion for the year due to the expiration of royalties on sales outside the U.S. Revenues from other products in the quarter were $14 million, compared to $10 million in 4Q08, and for the year were $54 million, compared to $49 million FY08.